Vendor comparison · 2026
Larazotide vendors: 0 compared on COAs and price
Tissue & recoveryAlso known as Larazotide acetate, AT-1001
Evidence tier
Moderate published literature
81 publications over 19 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 81
- researched since 2007
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Larazotide certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for Larazotide is on record. 0 vendors carrying Larazotide are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Larazotide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of Larazotide is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Larazotide names a laboratory this index could identify.
Every certificate record
No certificate record for Larazotide is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2007 — 19 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
81 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Larazotide?
Larazotide acetate, a synthetic octapeptide studied as a tight-junction regulator (a zonulin antagonist) and investigated clinically in coeliac disease.
Studied in published research for intestinal barrier function and coeliac disease.
Regulatory status
Larazotide is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation — American journal of physiology. Gastrointestinal and liver physiology (2021)
Peer-reviewed article indexed in PubMed, published in American journal of physiology. Gastrointestinal and liver physiology (2021).
- Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials — Clinics and research in hepatology and gastroenterology (2022)
Peer-reviewed article indexed in PubMed, published in Clinics and research in hepatology and gastroenterology (2022).
- Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment — Journal of controlled release : official journal of the Controlled Release Society (2025)
Peer-reviewed article indexed in PubMed, published in Journal of controlled release : official journal of the Controlled Release Society (2025).
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide — Science translational medicine (2025)
Peer-reviewed article indexed in PubMed, published in Science translational medicine (2025).
- Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection — European heart journal (2023)
Peer-reviewed article indexed in PubMed, published in European heart journal (2023).
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases — Current medicinal chemistry (2021)
Peer-reviewed article indexed in PubMed, published in Current medicinal chemistry (2021).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.